PMID- 37051286
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230415
IS  - 2325-9671 (Print)
IS  - 2325-9671 (Electronic)
IS  - 2325-9671 (Linking)
VI  - 11
IP  - 4
DP  - 2023 Apr
TI  - Determining the Time Required to Achieve Clinically Significant Outcomes on the 
      PROMIS Upper Extremity Questionnaire After Arthroscopic Rotator Cuff Repair.
PG  - 23259671231157038
LID - 10.1177/23259671231157038 [doi]
LID - 23259671231157038
AB  - BACKGROUND: Clinically significant outcome (CSO) thresholds for the 
      Patient-Reported Outcome Measurement Information System-Upper Extremity 
      (PROMIS-UE) score have been previously defined after arthroscopic rotator cuff 
      repair (RCR). However, the time required to achieve CSOs for the PROMIS-UE score 
      is unknown. PURPOSE: To (1) determine the time required to achieve the minimal 
      clinically important difference (MCID), substantial clinical benefit (SCB), and 
      Patient Acceptable Symptom State (PASS) score thresholds after RCR for the 
      PROMIS-UE questionnaire and (2) identify patient factors associated with earlier 
      or delayed achievement of these clinical benchmarks. STUDY DESIGN: Case-control 
      study; Level of evidence, 3. METHODS: A prospectively maintained institutional 
      database was retrospectively reviewed for consecutive patients who underwent RCR 
      between January 2018 and January 2019. Patients were included if they completed 
      the PROMIS-UE questionnaire both preoperatively and at standardized postoperative 
      time intervals: 5 to 7 months (6-month time point), 11 to 13 months (1-year time 
      point), and >/=23 months (2-year time point). Kaplan-Meier survival curves with 
      interval censoring were used to define the cumulative percentage of patients who 
      achieved the MCID, SCB, and PASS. Patient variables associated with earlier or 
      delayed achievement of the MCID, SCB, and PASS were determined using Weibull 
      parametric survival regression analysis. RESULTS: Included were 105 patients 
      undergoing RCR (age, 57.3 +/- 10.3 years; body mass index, 31.5 +/- 6.1 kg/m(2)). By 
      2-year follow-up, the cumulative percentage of patients achieving the MCID, SCB, 
      and PASS was 86.7%, 76.2%, and 74.3%, respectively. The mean time required to 
      reach the MCID, SCB, and PASS score thresholds was 9.5 +/- 3.8, 10.3 +/- 4.4, and 9.8 
      +/- 4.6 months, respectively. Factors associated with delayed achievement of CSOs 
      included greater baseline PROMIS-UE score (MCID and SCB) and workers' 
      compensation insurance (PASS). Greater baseline PROMIS-UE scores were associated 
      with earlier achievement of the PASS. CONCLUSION: Most patients achieved CSOs for 
      the PROMIS-UE within 12 months of RCR. Patient-specific factors found to be 
      associated with earlier or delayed achievement of CSOs can be used to inform 
      patient discussions on the expected timeline for recovery after RCR.
CI  - (c) The Author(s) 2023.
FAU - Polce, Evan M
AU  - Polce EM
AD  - School of Medicine and Public Health, University of Wisconsin, Madison, 
      Wisconsin, USA.
FAU - Vadhera, Amar S
AU  - Vadhera AS
AD  - Department of Orthopaedic Surgery, Midwest Orthopaedics at Rush, Rush University 
      Medical Center, Chicago, Illinois, USA.
FAU - Fu, Michael C
AU  - Fu MC
AD  - Department of Orthopaedic Surgery, Hospital for Special Surgery, New York, New 
      York, USA.
FAU - Singh, Harsh
AU  - Singh H
AD  - Department of Orthopaedic Surgery, Midwest Orthopaedics at Rush, Rush University 
      Medical Center, Chicago, Illinois, USA.
FAU - Haunschild, Eric D
AU  - Haunschild ED
AD  - Department of Orthopaedic Surgery, Mount Sinai Health System, New York, New York, 
      USA.
FAU - Garrigues, Grant E
AU  - Garrigues GE
AD  - Department of Orthopaedic Surgery, Midwest Orthopaedics at Rush, Rush University 
      Medical Center, Chicago, Illinois, USA.
FAU - Yanke, Adam B
AU  - Yanke AB
AD  - Department of Orthopaedic Surgery, Midwest Orthopaedics at Rush, Rush University 
      Medical Center, Chicago, Illinois, USA.
FAU - Forsythe, Brian
AU  - Forsythe B
AD  - Department of Orthopaedic Surgery, Midwest Orthopaedics at Rush, Rush University 
      Medical Center, Chicago, Illinois, USA.
FAU - Cole, Brian J
AU  - Cole BJ
AD  - Department of Orthopaedic Surgery, Midwest Orthopaedics at Rush, Rush University 
      Medical Center, Chicago, Illinois, USA.
FAU - Verma, Nikhil N
AU  - Verma NN
AD  - Department of Orthopaedic Surgery, Midwest Orthopaedics at Rush, Rush University 
      Medical Center, Chicago, Illinois, USA.
LA  - eng
PT  - Journal Article
DEP - 20230404
PL  - United States
TA  - Orthop J Sports Med
JT  - Orthopaedic journal of sports medicine
JID - 101620522
PMC - PMC10084545
OTO - NOTNLM
OT  - Kaplan-Meier survival analysis
OT  - Patient Acceptable Symptom State
OT  - Patient-Reported Outcome Measurement Information System
OT  - minimal clinically important difference
OT  - rotator cuff repair
OT  - substantial clinical benefit
COIS- One or more of the authors has declared the following potential conflict of 
      interest or source of funding: M.C.F. has received grant support from Acumed and 
      Arthrex; education payments from Medwest, Smith & Nephew, and Zimmer; consulting 
      fees from Encore Medical; and hospitality payments from Stryker. G.E.G. has 
      received consulting fees from AzurMeds, Bioventus, DePuy, Encore Medical, 
      Stryker, and Wright Medical; nonconsulting fees from Wright Medical; royalties 
      from Encore Medical, Stryker, and Wright Medical; honoraria from Wright Medical; 
      and hospitality payments from Arthrex and Smith & Nephew. A.B.Y. has received 
      education payments from Medwest, consulting fees from JRF Ortho and Olympus 
      America; nonconsulting fees from Arthrex; honoraria from JRF Ortho; and 
      hospitality payments from Stryker. B.F. has received education payments from 
      Medwest and consulting fees from Stryker. B.J.C. has received education payments 
      from Endo Pharmaceuticals; consulting fees from Acumed, Aesculap Biologics, Anika 
      Therapeutics, Bioventus, Endo Pharmaceuticals, Flexion Therapeutics, Geistlich 
      Pharma North America, Ossic, Ossio, Pacira Pharmaceuticals, Smith & Nephew, and 
      Vericel; nonconsulting fees from Aesculap Biologics, Arthrex, LifeNet Health, 
      Pacira Pharmaceuticals, and Terumo BCT; royalties from Arthrex; honoraria from 
      Vericel; and hospitality payments from GE Healthcare. N.N.V. has received 
      education payments from Medwest; consulting fees from Arthrex, Medacta, Smith & 
      Nephew, and Stryker; nonconsulting fees from Arthrex and Smith & Nephew; 
      royalties from Arthrex, Smith & Nephew, and Graymont Professional Products; and 
      hospitality payments from Relievant Medsystems. AOSSM checks author disclosures 
      against the Open Payments Database (OPD). AOSSM has not conducted an independent 
      investigation on the OPD and disclaims any liability or responsibility relating 
      thereto.
EDAT- 2023/04/14 06:00
MHDA- 2023/04/14 06:01
PMCR- 2023/04/04
CRDT- 2023/04/13 02:00
PHST- 2022/11/28 00:00 [received]
PHST- 2023/01/01 00:00 [accepted]
PHST- 2023/04/14 06:01 [medline]
PHST- 2023/04/13 02:00 [entrez]
PHST- 2023/04/14 06:00 [pubmed]
PHST- 2023/04/04 00:00 [pmc-release]
AID - 10.1177_23259671231157038 [pii]
AID - 10.1177/23259671231157038 [doi]
PST - epublish
SO  - Orthop J Sports Med. 2023 Apr 4;11(4):23259671231157038. doi: 
      10.1177/23259671231157038. eCollection 2023 Apr.